<DOC>
	<DOCNO>NCT01291121</DOCNO>
	<brief_summary>The main objective determine efficacy intravitreal administration Ranibizumab combine intravitreous injection expansile gas induction posterior vitreous detachment best-corrected visual acuity ocular coherence tomography ( OCT ) macular thickness subject neovascular age-related macular degeneration ( AMD ) posterior vitreomacular adhesion ( VMA ) . Secondary objective assess safety tolerability intravitreal administration Ranibizumab combine intravitreous injection expansile gas .</brief_summary>
	<brief_title>Intravitreal Ranibizumab Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion</brief_title>
	<detailed_description>Age-related macular degeneration ( AMD ) lead cause severe visual loss industrialized country . In recent year , advent anti-vascular endothelial growth factor ( VEGF ) therapy , ranibizumab bevacizumab , revolutionize neovascular AMD treatment anti-VEGF become standard treatment choroidal neovascularization ( CNV ) well visual outcome previous therapy photodynamic therapy ( PDT ) . However , one study report 45 % case ( 20 44 eye ) non-responders show resistance anti-VEGF . In case , visual acuity improve persistent subretinal fluid remain despite usual monthly injection anti-VEGF . A current focus anti-VEGF treatment determine eye respond treatment . To date , three genetic study response treatment wet AMD show specific genotype complement factor H LOC gene associate treatment response . Previous study describe relationship posterior vitreous macula AMD suggest vitreomacular adhesion ( VMA ) play important role development exudative AMD . In recent pair eye study , control confound variable select patient unilateral exudative AMD , show eye exudative AMD significantly high incidence posterior VMA pair normal eye ( P=0.0007 ) . This result indicate VMA possible risk factor exudative AMD . In another recent study , Mojana co-worker report improvement VA 25-gauge trans par plana vitrectomy ( TPPV ) hyaloid removal five patient history demonstrable VMA poorly responsive CNV despite aggressive anti-VEGF therapy . We postulate subpopulation exudative AMD case respond anti-VEGF therapy VMA may play role resistance therapy . The recent result study indicate posterior VMA negative effect visual outcome intravitreal anti-VEGF treatment exudative AMD . BCVA improve eye posterior VMA despite anti-VEGF treatment . Posterior hyaloid removal intravitreous injection expansile gas induction posterior vitreous detachment may consider treatment option patient VMA poor responder anti-VEGF treatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Vitreous Detachment</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Age &gt; 50 year old 2 . Exudative AMD proven fundus photograph fluorescein angiography ( FA ) VMA proven OCT 3 . Ability provide write informed consent comply study assessment 1 . Previous antiVEGF treatment 2 . More three prior treatment PDT 3 . Previous subfoveal focal laser photocoagulation study eye 4 . Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within 1 month precede day 0 5 . Subfoveal fibrosis atrophy study eye 6 . History vitrectomy surgery study eye 7 . Significant concurrent ocular macular disease study eye 8. medical Hx myocardial infarction , cerebrovascular accident , ischemic cardiomyopathy , non ocular hemorrhage 9 . History Ranibizumab hypersensitivity 10 . Presence active periocular infection and/or endophthalmitis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Age relate macular degeneration</keyword>
	<keyword>Intravitreal ranibizumab</keyword>
	<keyword>Intravitreal expansile gas injection</keyword>
</DOC>